United States Biosimilar Market Report by Molecule (Infliximab, Insulin Glargine, Epoetin Alfa, Etanercept, Filgrastim, Somatropin, Rituximab, Follitropin Alfa, Adalimumab, Pegfilgrastim, Trastuzumab, Bevacizumab, and Others), Manufacturing Type (In-House Manufacturing, Contract Manufacturing), Indication (Auto-Immune Diseases, Blood Disorder, Diabetes, Oncology, Growth Deficiency, Female Infertility, and Others), and Region 2024-2032

United States Biosimilar Market Report by Molecule (Infliximab, Insulin Glargine, Epoetin Alfa, Etanercept, Filgrastim, Somatropin, Rituximab, Follitropin Alfa, Adalimumab, Pegfilgrastim, Trastuzumab, Bevacizumab, and Others), Manufacturing Type (In-House Manufacturing, Contract Manufacturing), Indication (Auto-Immune Diseases, Blood Disorder, Diabetes, Oncology, Growth Deficiency, Female Infertility, and Others), and Region 2024-2032

Report Format: PDF+Excel | Report ID: SR112024A11073
Buy Now

Market Overview:

The United States biosimilar market size is projected to exhibit a growth rate (CAGR) of 19.3% during 2024-2032. The increasing need for cost-effective treatments due to rising healthcare costs, the escalating number of collaborations and partnerships between companies, and investment in education and clear communication strategies around biosimilars are some of the key factors driving the market.

Report Attribute 
Key Statistics
Base Year
2023
Forecast Years
2024-2032
Historical Years
2018-2023
Market Growth Rate 2024-2032 19.3%


A biosimilar refers to a biological product that closely resembles a biologic medication that has previously received regulatory approval. It is designed to have the same efficacy, safety, and quality as the original, or "reference," biologic drug. It is used to treat a wide range of diseases and conditions including cancer, diabetes, and autoimmune disorders. Though similar to the reference product, biosimilars are not considered generic versions, as their complex nature requires careful development and manufacturing processes. Regulatory authorities, such as the FDA, follow stringent guidelines to evaluate biosimilars, ensuring they meet all necessary requirements. The introduction of biosimilars into the market provides additional treatment options for patients and healthcare providers, often at a reduced cost compared to the original biologics. The production of biosimilars fosters competition, possibly leading to more affordable healthcare solutions without compromising the quality of treatment. It encourages innovation within the pharmaceutical industry, thus contributing positively to healthcare accessibility. Through their blend of quality, effectiveness, and cost-efficiency, biosimilars stand as an essential component in the evolving landscape of healthcare and therapeutic management.

United States Biosimilar Market Trends:

The increasing need for cost-effective treatments due to rising healthcare costs is a major driver stimulating the growth of biosimilars. With the expiration of patents for several biologic drugs, the biosimilar industry has seen a rise in development, providing affordable alternatives to patients. Regulatory support, such as abbreviated pathways for biosimilar approval in the country, is further boosting the market. Additionally, the aging population in many developed countries, coupled with a higher prevalence of chronic diseases, such as cancer and diabetes, necessitates the demand for these less-expensive therapeutic alternatives, thereby contributing to its demand. Along with this, collaborations and partnerships between companies are fostering innovation, broadening the reach of biosimilars across different markets. Apart from this, the widespread acceptance and adoption of biosimilars by healthcare professionals and patients across the country have been enhanced by increasing awareness and understanding of the safety and efficacy of these products. Furthermore, investment in education and clear communication strategies around biosimilars ensures an informed choice, further driving market growth. Together, these factors create a conducive environment for the biosimilar industry, promoting increased accessibility, affordability, and innovation in healthcare treatments. Other factors, including rapid digitization, continuous product innovations, continual technological advancements, continual developments in the healthcare sector and extensive research and development (R&D) activities conducted by key players, are also positively influencing the market across the United States.

United States Biosimilar Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the United States biosimilar market report, along with forecasts at the country level for 2024-2032. Our report has categorized the market based on molecule, manufacturing type, and indication.

Molecule Insights:

  • Infliximab
  • Insulin Glargine
  • Epoetin Alfa
  • Etanercept
  • Filgrastim
  • Somatropin
  • Rituximab
  • Follitropin Alfa
  • Adalimumab
  • Pegfilgrastim
  • Trastuzumab
  • Bevacizumab
  • Others
     

The report has provided a detailed breakup and analysis of the market based on the molecule. This includes infliximab, insulin glargine, epoetin alfa, etanercept, filgrastim, somatropin, rituximab, follitropin alfa, adalimumab, pegfilgrastim, trastuzumab, bevacizumab, and others.

Manufacturing Type Insights:

  • In-house Manufacturing
  • Contract Manufacturing
     

A detailed breakup and analysis of the market based on the manufacturing type have also been provided in the report. This includes in-house manufacturing and contract manufacturing.

Indication Insights:

  • Auto-Immune Diseases
  • Blood Disorder
  • Diabetes
  • Oncology
  • Growth Deficiency
  • Female Infertility
  • Others
     

The report has provided a detailed breakup and analysis of the market based on the indication. This includes auto-immune diseases, blood disorder, diabetes, oncology, growth deficiency, female infertility, and others.

Regional Insights:

  • Northeast
  • Midwest
  • South
  • West
     

The report has also provided a comprehensive analysis of all the major regional markets, which include the Northeast, Midwest, South, and West.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the market. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

United States Biosimilar Market Report Coverage:

Report Features Details
Base Year of the Analysis 2023
Historical Period 2018-2023
Forecast Period 2024-2032
Units US$ Million
Scope of the Report Exploration of Historical and Forecast Trends, Industry Catalysts and Challenges, Segment-Wise Historical and Predictive Market Assessment: 
  • Molecule
  • Manufacturing Type
  • Indication
  • Region
Molecules Covered Infliximab, Insulin Glargine, Epoetin Alfa, Etanercept, Filgrastim, Somatropin, Rituximab, Follitropin Alfa, Adalimumab, Pegfilgrastim, Trastuzumab, Bevacizumab, Others
Manufacturing Types Covered In-House Manufacturing, Contract Manufacturing
Indications Covered Auto-Immune Diseases, Blood Disorder, Diabetes, Oncology, Growth Deficiency, Female Infertility, Others
Regions Covered Northeast, Midwest, South, West
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 3699
Five User License: US$ 4699
Corporate License: US$ 5699
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Key Questions Answered in This Report:

  • How has the United States biosimilar market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the United States biosimilar market?
  • What is the breakup of the United States biosimilar market on the basis of molecule?
  • What is the breakup of the United States biosimilar market on the basis of manufacturing type?
  • What is the breakup of the United States biosimilar market on the basis of indication?
  • What are the various stages in the value chain of the United States biosimilar market?
  • What are the key driving factors and challenges in the United States biosimilar market?
  • What is the structure of the United States biosimilar market and who are the key players?
  • What is the degree of competition in the United States biosimilar market?

Key Benefits for Stakeholders:

  • IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the United States biosimilar market from 2018-2032.
  • The research study provides the latest information on the market drivers, challenges, and opportunities in the United States biosimilar market.
  • Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the United States biosimilar industry and its attractiveness.
  • Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
United States Biosimilar Market Report by Molecule (Infliximab, Insulin Glargine, Epoetin Alfa, Etanercept, Filgrastim, Somatropin, Rituximab, Follitropin Alfa, Adalimumab, Pegfilgrastim, Trastuzumab, Bevacizumab, and Others), Manufacturing Type (In-House Manufacturing, Contract Manufacturing), Indication (Auto-Immune Diseases, Blood Disorder, Diabetes, Oncology, Growth Deficiency, Female Infertility, and Others), and Region 2024-2032
Purchase options




Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-713-2163

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARTI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More